#GiOnc hashtag - Bluesky

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

4 weeks ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRQxmX
@ASCO

#SocialListening #LucidQuest

0 0 0 0

Lingling Tian

@linglingtian.bsky.social

4 weeks ago

Ther Adv Med Oncol: Real‑world comparison of mFOLFOX‑6 vs mDCF in metastatic gastric/GEJ cancer (n=493, 25 hospitals):
• PFS: 7 vs 6 mo
• OS: 11 vs 12 mo
• Similar ORR
• Lower grade 3–4 neutropenia/anemia with mFOLFOX‑6
Read: 【🔗https://buff.ly/kUKcGAz 】
#GastricCancer #GIOnc #Chemotherapy

1 1 0 0

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

1 month ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TRF805
@ASCO

#SocialListening #LucidQuest

0 0 0 0

Therapeutic Advances in Medical Oncology

@tamedoncol.bsky.social

1 month ago

Real‑world evidence in Ther Adv Med Onc shows nal‑IRI/5‑FU/LV significantly improves OS in pancreatic adenocarcinoma (28.0 vs 18.3 months) despite higher cost (ICER $33,285/LYG). 🔗https://buff.ly/dOq2XvY
#PancreaticCancer #GIOnc #RealWorldEvidence #HealthEconomics

1 1 0 0

ASCO GI 2025 SoMe Report.pdf

1 month ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TR4sCY
@ASCO

#SocialListening #LucidQuest

0 0 0 0

ASCO GI 2025 SoMe Report.pdf

1 month ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQvxV7
@ASCO

#SocialListening #LucidQuest

0 0 0 0

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

2 months ago

Excellent work summarizing #pancsm studies @graokane.bsky.social #GIonc @oncoalert.bsky.social #GIonc

0 0 0 0

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

2 months ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQkJJF
@ASCO

#SocialListening #LucidQuest

0 0 0 0

10 Must-Read Posts in GI Oncology This Week - OncoDaily 10 Must-Read Posts in GI Oncology This Week / cancer, cancer care, cancer treatment, clinical trials, colorectal cancer, esophageal cancer, gastric cancer, GI

2 months ago

10 Must-Read Posts in GI Oncology This Week

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc

2 1 0 0

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

2 months ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQYRN4
@ASCO

#SocialListening #LucidQuest

0 0 0 0

10 Must-Read Posts in GI Oncology This Week - OncoDaily 10 Must-Read Posts in GI Oncology This Week / Biliary tract cancer (BTC), cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical

2 months ago

10 Must-Read Posts in GI Oncology This Week

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc

1 0 0 0

ASCO GI 2025 SoMe Report.pdf Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.

2 months ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQPfK2
@ASCO

#SocialListening #LucidQuest

0 0 0 0

ASCO GI 2025 SoMe Report.pdf

3 months ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQFj65
@ASCO

#SocialListening #LucidQuest

0 0 0 0

ONCOassist® | The go-to oncology app

@oncoassist.bsky.social

3 months ago

✔️ Evidence-aligned, clinician-reviewed
✔️ Ideal for exam preparation & refreshers
✔️ See how you rank on the global leaderboard

#Gastric #GastricCancer #Oncology #OncoIQ #MedicalEducation #GIOnc

0 0 0 0

GALAXY Study: Postoperative ctDNA as a Prognostic and Predictive Biomarker in Stage II–III Rectal Cancer - OncoDaily GALAXY Study shows postoperative ctDNA predicts recurrence risk and adjuvant chemotherapy benefit in stage II–III rectal cancer after upfront surgery.

3 months ago

GALAXY Study: Postoperative ctDNA as a Prognostic and Predictive Biomarker in Stage II–III Rectal Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GALAXY #RectalCancer #GIOnc

2 0 0 0

Yan Leyfman: ctDNA Dynamics Predict Outcomes in Advanced Gastroesophageal Cancer - OncoDaily Yan Leyfman: ctDNA Dynamics Predict Outcomes in Advanced Gastroesophageal Cancer / Adham A. Jurdi, Bushra Shariff, cancer, Farshid Dayyani, gastroesophageal

3 months ago

ctDNA Dynamics Predict Outcomes in Advanced Gastroesophageal Cancer - Yan Leyfman

@yleyfman.bsky.social

oncodaily.com/voices/yan-l...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc #GastroesophagealCancer

3 0 1 0

10 Must-Read Posts in GI Oncology This Week - OncoDaily 10 Must-Read Posts in GI Oncology This Week / Biliary tract cancer (BTC), cancer, cancer care, Cancer research, cancer treatment, chemotherapy, clinical

3 months ago

10 Must-Read Posts in GI Oncology This Week

oncodaily.com/opinion/10-m...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc

2 0 0 0

Resectable Esophageal Adenocarcinoma: A Comparative Analysis of Divergent Outcomes With FLOT and CROSS in Trial and Real-World Settings - OncoDaily Understanding Divergent Outcomes With FLOT and CROSS in Resectable Esophageal Adenocarcinoma: Trial and Real-World Evidence

3 months ago

Resectable Esophageal Adenocarcinoma: A Comparative Analysis of Divergent Outcomes With FLOT and CROSS in Trial and Real-World Settings

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EsophagealAdenocarcinoma #GIOnc #FLOT #CROSS

3 0 0 0

2025 Through the lens of OncoDaily GI: Building a Focused Voice in Gastrointestinal Oncology - OncoDaily 2025 Through the lens of OncoDaily GI: Building a Focused Voice in Gastrointestinal Oncology / Biliary tract cancer, cancer, cancer awareness, cancer care,

3 months ago

2025 Through the Lens of OncoDaily GI: Building a Focused Voice in Gastrointestinal Oncology

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc #OncoDailyGI

2 0 0 0

ASCO GI 2025 SoMe Report.pdf 403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

3 months ago

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TQ6Y9Q
@ASCO

#SocialListening #LucidQuest

0 0 0 0